

Your abstract submission has been received

Print this page

You have submitted the following abstract to the ASRM 2025 Scientific Congress & Expo. Receipt of this notice does not guarantee that your submission was complete or free of errors.

PREDICTING TREATMENT FUTILITY IN PATIENTS UNDERGOING AUTOLOGOUS IVF

Jensen Reckhow, MD, MPH¹, Miriam A Andrusier, MD, MPH¹, Carlos Hernandez-Nieto, MD², Morgan Baird, MPH², Sasha Layne, MS², Joseph A. Lee, BA², Alan B. Copperman, M.D.³ and Daniel E. Stein, M.D.², (1)Icahn School of Medicine at Mount Sinai, New York, NY, (2)Reproductive Medicine Associates of New York, New York, NY, (3)Icahn School of Medicine at Mount Sinai/Reproductive Medicine Associates of New York, New York, NY

Title:

PREDICTING TREATMENT FUTILITY IN PATIENTS UNDERGOING AUTOLOGOUS IVF

Submitter's E-mail Address:

jensen.reckhow@usfertility.com

Preferred Presentation Type:

Oral or Poster

Study Type:

Retrospective Cohort Study (includes comparator groups)

Category - Subcategory(ies):

Patient Centered Care: Education & Information

* Submission of an abstract for consideration for presentation implies that the presenting author & associated co-authors have legal and ethical rights to submit and present this work. Plagiarism and submitting work that an author has no rights to, will result in an investigation and penalty.

* I verify that I am in compliance with HIPAA standards to protect the privacy of the patients discussed in my presentation(s). I either have received written authorization from the patient, have removed any identifiable images or patient records from my presentation, or my presentation does not pertain to patient treatment.

Permissions - Prior Publication or Presentation

This abstract contains original work, not published or presented previously at a meeting of another national or international scientific organization prior to this meeting and has not been submitted for publication at the time of this submission.

ACCME Disclosure

Nothing to disclose. No off-label or otherwise non-approved product use.

Did this abstract require approval by a local Institutional Review Board (IRB) or equivalent?

This abstract has been approved by a local Institutional Review Board (IRB) or equivalent.

Applying for an award

Trainee: Yes

Abstract Category:

All Other Categories

Applied for the In-Training Award for Research**Abstract Text:**

OBJECTIVE: The goal of assisted reproductive technology (ART) is to support patients in building the family they envision, with live birth as the ultimate goal. However, ART demands significant

physical, emotional, and financial investment, making strategic treatment planning essential. This study aimed to identify cycle characteristics associated with failure to achieve live birth when utilizing ART.

MATERIALS AND METHODS: This retrospective cohort study conducted at a single academic institution included autologous in vitro fertilization (IVF) cycles and subsequent single euploid embryo transfers (SEET) between January 2016 and December 2024. The primary outcome was live birth. Secondary outcomes included cycle cancellation prior to oocyte retrieval, number of oocytes retrieved, number of embryos suitable for biopsy or rescue transfer, and the chances of pregnancy. Patient and cycle characteristics analyzed included patient age, anti-mullerian hormone (AMH, ng/mL), follicle-stimulating hormone (FSH, IU/L), and antral follicle count (AFC) at cycle start. Descriptive statistics were applied and receiver operating characteristic (ROC) curves with Youden indices were used to identify threshold values of predictors of the primary outcome.

RESULTS: A total of 8,740 patients who underwent 11,252 IVF cycles with 15,383 subsequent SEET cycles were included. The oldest oocyte age resulting in a live birth was 45.8 years, and no patients who underwent SEET above age 47.7 achieved a live birth regardless of oocyte age of the embryo transferred. When analyzing IVF cycles, the highest basal FSH level resulting in a live birth was 22.3. No patients above age 43.3 and FSH>10 (n=188) at the time of ovarian stimulation achieved a live birth, and no patients above age 41 and FSH>15 (n=173) achieved a live birth. The lowest AMH level at the time of IVF associated with a live birth was 0.03, while the lowest AMH level for patients >42 years old was 0.23. No patients >42 years old achieved a live birth with an AFC <4 (n=279) during the IVF cycle. All IVF cycles initiated in patients older than 46 resulted in cycle cancellation (n=85), with 75.3% (n=64) cancelled due to poor response during stimulation, 2.4% (n=2) cancelled due to no oocytes retrieved, and 22.3% (n=19) cancelled due to lack of embryos suitable for transfer or cryostorage. Among patients aged >41, 55.2% (n=1140/2065) experienced cycle cancellation. Among patients aged >45 years (n=175), 94.3% (n=164) experienced cycle cancellation. However, of the 11 patients in this age group who did produce an embryo suitable for transfer, 7 achieved a live birth.

CONCLUSIONS: A majority of patients over the age of 41 undergoing autologous IVF will experience cycle cancellation prior to SEET. For patients over 46, consideration of alternative options, such as donor oocytes, may offer the best opportunity for achieving a live birth.

IMPACT STATEMENT: For patients with advanced maternal age or other poor prognosis factors, understanding the roles of oocyte age, AMH, AFC, and baseline FSH can help guide personalized treatment plans and set realistic expectations, providing insight into when alternative approaches, such as use of donor oocytes, may improve chances of success.

First Presenting Author

Presenting Author

Jensen Reckhow, MD, MPH

Email: jensen.reckhow@usfertility.com -- Will not be published

Icahn School of Medicine at Mount Sinai
Department of Obstetrics, Gynecology, and Reproductive Science
1176 Fifth Ave, Klingenstein Pavilion
9th floor
New York NY 10029
USA

Biographical Sketch Jensen Reckhow is a PGY-3 Resident in Obstetrics and Gynecology at Mayo Clinic. She completed her BS in Environmental Engineering and MPH at Yale University. She conducted translational immunology research at NIH for two years prior to attending Ben Gurion University in Israel for medical school. This is her first time attending and presenting at ASRM and she is looking forward to learning from this passionate and inspiring community.

Within the past 2 years, have you or your spouse/partner had any potential COI?

No

Signature: Jensen Reckhow, MD, MPH



CV Upload:

 [Jensen Reckhow CV 3.10.2025.docx](#)

Second Author

Miriam A Andrusier, MD, MPH

Email: miriamandrusier1@gmail.com -- Will not be published

Icahn School of Medicine at Mount Sinai
Department of Obstetrics, Gynecology, and Reproductive Science
1176 Fifth Ave, Klingenstein Pavilion
9th floor
New York NY 10029
USA


Within the past 2 years, have you or your spouse/partner had any potential COI?

No

Signature: Miriam Andrusier, MD, MPH



CV Upload:

 [Miriam Andrusier CV.docx](#)

Third Author

Carlos Hernandez-Nieto, MD

Email: chernandez@rmany.com -- Will not be published

Reproductive Medicine Associates of New York
635 Madison Ave 10th Fl
New York NY 10022-1009
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?

No

Signature: Carlos Hernandez-Nieto

**CV Upload:**

 CHN CV Apr24.docx

Fourth Author

Morgan Baird, MPH

Email: mbaird@rmaofny.com -- Will not be published

Reproductive Medicine Associates of New York
635 Madison Avenue
10th Fl.
New York NY 10022-1009
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?

No

Signature: Morgan Baird, MPH

Fifth Author

Sasha Layne, MS

Email: SLayne@rmaofny.com -- Will not be published

Reproductive Medicine Associates of New York
635 Madison Ave 10th Fl
New York NY 10022-1009
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?

No

Signature: Sasha Layne, MS

Sixth Author

Joseph A. Lee, BA

Email: jlee@rmany.com -- Will not be published

Reproductive Medicine Associates of New York
635 Madison Ave 10th Fl
New York NY 10022-1009
USA

Biographical Sketch Early success, marked by his first publication in CELL at Harvard Medical School, inspired Joseph to continue his research endeavors in reproductive endocrinology and infertility. Joseph has been with Reproductive Medicine Associates of New York since 2011. Joseph has authored over 400 peer-reviewed abstracts & manuscripts. Passionate about development, he cultivates relationship with investors & entrepreneurs to advance reproductive endocrinology & infertility care.

Within the past 2 years, have you or your spouse/partner had any potential COI?

No

Signature: Joseph Adam Lee



CV Upload:

 [Joseph Lee CV.docx](#)

Seventh Author

Alan B. Copperman, M.D.

Email: acopperman@rmany.com -- Will not be published

Icahn School of Medicine at Mount Sinai/Reproductive Medicine Associates of New York
 Department of Obstetrics, Gynecology, and Reproductive Science
 New York NY
 USA

Within the past 2 years, have you or your spouse/partner had any potential COI?
 Yes

| Organization Name | Relationship Type | Who has this Relationship? |
|-------------------|--|----------------------------|
| Progyny | Company Officer Relationship Began - Friday, August 25, 2017 Relationship Ended - Thursday, June 1, 2023 Paid Consultant Relationship Began - Relationship Ended - Direct Stockholder Relationship Began - Friday, August 25, 2017 Relationship Ended - Friday, November 1, 2024 | Self |

Signature: Alan B Copperman



CV Upload:

 [Alan B. Copperman M.D. - CV \(March 2024\).docx](#)

Eighth Author

Daniel E. Stein, M.D.
Email: dstein@rmany.com -- Will not be published

Reproductive Medicine Associates of New York
 635 Madison Ave 10th Fl

New York NY 10022-1009
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?

No

Signature: Daniel E Stein, M.D.

If necessary, you can make changes to your abstract submission until Wednesday, April 30, 2025 at 4:00 pm (EDT).

To access your submission in the future, use the link to your user portal from one of the automatic confirmation emails that were sent to you during the submission.

Or point your browser to <https://asrm.confex.com/asrm/2025/gateway.cgi>

You will be prompted to login with your ASRM account prior to accessing the user portal. If you do not yet have an ASRM account, the screen will redirect you to the site where you can register for a new account.

When registering for a new ASRM account:

- Please use the email address that is associated with the submission and your first and last name as they appear on the submission when creating this account.
- An ASRM account for login must be completed before you can access the user portal.

Any changes that you make will be reflected instantly in what is seen by the reviewers. You DO NOT need to go through all of the submission steps in order to change one thing. If you want to change the title, for example, just click "Title" in the abstract control panel and submit the new title.

When you have completed your submission, you may close this browser window.

If you would like to submit another abstract, click [here](#).

[Tell us what you think of the abstract submission process](#)

[Home Page](#)